JPWO2019191092A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191092A5 JPWO2019191092A5 JP2020552026A JP2020552026A JPWO2019191092A5 JP WO2019191092 A5 JPWO2019191092 A5 JP WO2019191092A5 JP 2020552026 A JP2020552026 A JP 2020552026A JP 2020552026 A JP2020552026 A JP 2020552026A JP WO2019191092 A5 JPWO2019191092 A5 JP WO2019191092A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazine
- amino
- phenol
- pyrazole
- tetramethylpiperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1,2-dihydropyridinyl Chemical group 0.000 claims 93
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000004076 pyridyl group Chemical group 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 claims 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 claims 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical compound C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 claims 1
- HWRLEEPNFJNTOP-UHFFFAOYSA-N 2-(1,3,5-triazin-2-yl)phenol Chemical compound OC1=CC=CC=C1C1=NC=NC=N1 HWRLEEPNFJNTOP-UHFFFAOYSA-N 0.000 claims 1
- IKNUIKBFNNJXQD-UHFFFAOYSA-N 2-(5-piperidin-4-yloxypyrazin-2-yl)-5-(1H-pyrazol-4-yl)phenol Chemical compound N1CCC(CC1)OC=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O IKNUIKBFNNJXQD-UHFFFAOYSA-N 0.000 claims 1
- OASPCOJIXLTDNU-UHFFFAOYSA-N 2-(5-piperidin-4-yloxypyrazin-2-yl)-5-(1H-pyrazol-4-yl)phenol trihydrochloride Chemical compound Cl.Cl.Cl.N1CCC(CC1)OC=1N=CC(=NC1)C1=C(C=C(C=C1)C=1C=NNC1)O OASPCOJIXLTDNU-UHFFFAOYSA-N 0.000 claims 1
- DIGMVIFWRARWAA-UHFFFAOYSA-N 2-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-5-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyrazine Chemical compound FC1=C(C=CC(=C1F)C=1C=NNC=1)C1=NC=C(N=C1)OC1CC(NC(C1)(C)C)(C)C DIGMVIFWRARWAA-UHFFFAOYSA-N 0.000 claims 1
- DZQBYXJNUAVIBZ-UHFFFAOYSA-N 2-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-5-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyrazine trihydrochloride Chemical compound CC1(CC(CC(N1)(C)C)OC2=NC=C(N=C2)C3=C(C(=C(C=C3)C4=CNN=C4)F)F)C.Cl.Cl.Cl DZQBYXJNUAVIBZ-UHFFFAOYSA-N 0.000 claims 1
- PGJONQZOJFKMDI-UHFFFAOYSA-N 2-[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl)pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound C1N(CC2C1CNC2)C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O PGJONQZOJFKMDI-UHFFFAOYSA-N 0.000 claims 1
- AQPVVBVWDFPJIS-UHFFFAOYSA-N 2-[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl)pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride Chemical compound C1C2CN(CC2CN1)C3=NC=C(N=C3)C4=C(C=C(C=C4)C5=CNN=C5)O.Cl.Cl.Cl.Cl AQPVVBVWDFPJIS-UHFFFAOYSA-N 0.000 claims 1
- GGRSYZQGVRWXPJ-UHFFFAOYSA-N 2-[5-(2,7-diazaspiro[3.4]octan-2-yl)pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound C1N(CC11CNCC1)C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O GGRSYZQGVRWXPJ-UHFFFAOYSA-N 0.000 claims 1
- ZZCFEUQEEVGWKB-UHFFFAOYSA-N 2-[5-(piperidin-4-ylamino)pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound N1CCC(CC1)NC=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O ZZCFEUQEEVGWKB-UHFFFAOYSA-N 0.000 claims 1
- GSDATBBMDNCKCT-UHFFFAOYSA-N 2-[5-(piperidin-4-ylamino)pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride Chemical compound C1CNCCC1NC2=NC=C(N=C2)C3=C(C=C(C=C3)C4=CNN=C4)O.Cl.Cl.Cl.Cl GSDATBBMDNCKCT-UHFFFAOYSA-N 0.000 claims 1
- DJUDFYVWPSROQV-UHFFFAOYSA-N 2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-5-(triazol-2-yl)phenol Chemical compound CC1(C)CC(CC(C)(C)N1)NC1=NC=C(N=C1)C1=C(O)C=C(C=C1)N1N=CC=N1 DJUDFYVWPSROQV-UHFFFAOYSA-N 0.000 claims 1
- OZYCXOXQSURAGX-UHFFFAOYSA-N 2-[5-[2-hydroxy-4-(1H-pyrazol-4-yl)phenyl]pyrazin-2-yl]-2-(2,2,6,6-tetramethylpiperidin-4-yl)acetonitrile Chemical compound OC1=C(C=CC(=C1)C=1C=NNC=1)C=1N=CC(=NC=1)C(C#N)C1CC(NC(C1)(C)C)(C)C OZYCXOXQSURAGX-UHFFFAOYSA-N 0.000 claims 1
- HHTJEPSYVJFJSQ-UHFFFAOYSA-N 2-[5-[3-(tert-butylamino)pyrrolidin-1-yl]pyrazin-2-yl]-5-(1-methylpyrazol-4-yl)phenol Chemical compound C(C)(C)(C)NC1CN(CC1)C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NN(C=1)C)O HHTJEPSYVJFJSQ-UHFFFAOYSA-N 0.000 claims 1
- FLYPXFRSCMKLHG-UHFFFAOYSA-N 2-[5-[3-(tert-butylamino)pyrrolidin-1-yl]pyrazin-2-yl]-5-(1-methylpyrazol-4-yl)phenol dihydrochloride Chemical compound Cl.Cl.Cn1cc(cn1)-c1ccc(c(O)c1)-c1cnc(cn1)N1CCC(C1)NC(C)(C)C FLYPXFRSCMKLHG-UHFFFAOYSA-N 0.000 claims 1
- YPKUJWIGUBMAOC-UHFFFAOYSA-N 2-[5-[3-(tert-butylamino)pyrrolidin-1-yl]pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound C(C)(C)(C)NC1CN(CC1)C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O YPKUJWIGUBMAOC-UHFFFAOYSA-N 0.000 claims 1
- MJBABKMSSYHMCO-UHFFFAOYSA-N 2-[5-[3-(tert-butylamino)pyrrolidin-1-yl]pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride Chemical compound Cl.Cl.CC(C)(C)NC1CCN(C1)c1cnc(cn1)-c1ccc(cc1O)-c1cn[nH]c1 MJBABKMSSYHMCO-UHFFFAOYSA-N 0.000 claims 1
- HHTJEPSYVJFJSQ-GKOSEXJESA-N 2-[5-[3-(tert-butylamino)pyrrolidin-1-yl]pyrazin-2-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]phenol Chemical compound C(C)(C)(C)NC1CN(CC1)C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NN(C=1)C([2H])([2H])[2H])O HHTJEPSYVJFJSQ-GKOSEXJESA-N 0.000 claims 1
- FLYPXFRSCMKLHG-DULOSRJUSA-N 2-[5-[3-(tert-butylamino)pyrrolidin-1-yl]pyrazin-2-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]phenol dihydrochloride Chemical compound Cl.Cl.[2H]C([2H])([2H])n1cc(cn1)-c1ccc(c(O)c1)-c1cnc(cn1)N1CCC(C1)NC(C)(C)C FLYPXFRSCMKLHG-DULOSRJUSA-N 0.000 claims 1
- SVZIYQDLLKCYFU-UHFFFAOYSA-N 2-[5-[amino-(2,2,6,6-tetramethylpiperidin-4-yl)methyl]pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound NC(C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O)C1CC(NC(C1)(C)C)(C)C SVZIYQDLLKCYFU-UHFFFAOYSA-N 0.000 claims 1
- FKEBCGSHHBRTPF-UHFFFAOYSA-N 2-[5-[methyl(piperidin-4-yl)amino]pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound CN(C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O)C1CCNCC1 FKEBCGSHHBRTPF-UHFFFAOYSA-N 0.000 claims 1
- KYLQBJVOMJMWGU-UHFFFAOYSA-N 2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol hydrobromide Chemical compound Br.CN(C1CC(C)(C)NC(C)(C)C1)c1cnc(cn1)-c1ccc(cc1O)-c1cn[nH]c1 KYLQBJVOMJMWGU-UHFFFAOYSA-N 0.000 claims 1
- XXCBCHUIECDYDQ-UHFFFAOYSA-N 2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-5-(triazol-2-yl)phenol Chemical compound CN(C=1N=CC(=NC=1)C1=C(C=C(C=C1)N1N=CC=N1)O)C1CC(NC(C1)(C)C)(C)C XXCBCHUIECDYDQ-UHFFFAOYSA-N 0.000 claims 1
- CJBAWWOUMQLVHW-VPYROQPTSA-N 2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-5-[1-(trideuteriomethyl)pyrazol-4-yl]phenol Chemical compound C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C)([2H])([2H])[2H] CJBAWWOUMQLVHW-VPYROQPTSA-N 0.000 claims 1
- NXJUVYCMVOOVJT-UHFFFAOYSA-N 2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-5-pyrazol-1-ylphenol Chemical compound CN(C=1N=CC(=NC=1)C1=C(C=C(C=C1)N1N=CC=C1)O)C1CC(NC(C1)(C)C)(C)C NXJUVYCMVOOVJT-UHFFFAOYSA-N 0.000 claims 1
- AIPSUZCQFPSGLV-UHFFFAOYSA-N 4-[3-hydroxy-4-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl]-1H-pyrazole-5-carbonitrile Chemical compound OC=1C=C(C=CC=1C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C)C=1C=NNC=1C#N AIPSUZCQFPSGLV-UHFFFAOYSA-N 0.000 claims 1
- GTAYBMVFMPMRCY-UHFFFAOYSA-N 4-[3-hydroxy-4-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl]-1H-pyridin-2-one Chemical compound OC=1C=C(C=CC=1C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C)C1=CC(=NC=C1)O GTAYBMVFMPMRCY-UHFFFAOYSA-N 0.000 claims 1
- NAGODULBRRMYTM-UHFFFAOYSA-N 4-[3-hydroxy-4-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl]-2-methylpyrazole-3-carbonitrile Chemical compound OC=1C=C(C=CC=1C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C)C=1C=NN(C=1C#N)C NAGODULBRRMYTM-UHFFFAOYSA-N 0.000 claims 1
- BYRFQNHNCDBMBE-UHFFFAOYSA-N 4-fluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-5-(1H-pyrazol-4-yl)phenol Chemical compound FC1=CC(=C(C=C1C=1C=NNC=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C BYRFQNHNCDBMBE-UHFFFAOYSA-N 0.000 claims 1
- ZVLBHUOHQNYWPZ-UHFFFAOYSA-N 4-fluoro-5-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-2-(1H-pyrazol-4-yl)benzonitrile Chemical compound FC1=CC(=C(C#N)C=C1C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C)C=1C=NNC=1 ZVLBHUOHQNYWPZ-UHFFFAOYSA-N 0.000 claims 1
- CMDFZHYVQPQELQ-UHFFFAOYSA-N 5-(1,5-dimethylpyrazol-4-yl)-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CN1N=CC(=C1C)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C CMDFZHYVQPQELQ-UHFFFAOYSA-N 0.000 claims 1
- PQWKSBIYLLJDAM-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C PQWKSBIYLLJDAM-UHFFFAOYSA-N 0.000 claims 1
- CJBAWWOUMQLVHW-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C CJBAWWOUMQLVHW-UHFFFAOYSA-N 0.000 claims 1
- MCYFRMAVSYYRBB-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[5-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyrazin-2-yl]phenol Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)OC1CC(NC(C1)(C)C)(C)C MCYFRMAVSYYRBB-UHFFFAOYSA-N 0.000 claims 1
- QUOQPMKZWUYSKF-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[5-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyrazin-2-yl]phenol hydrochloride Chemical compound Cl.CC1(C)CC(CC(C)(C)N1)Oc1cnc(cn1)-c1ccc(cc1O)-c1cn[nH]c1 QUOQPMKZWUYSKF-UHFFFAOYSA-N 0.000 claims 1
- DUMYCWDXIVSOQM-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C DUMYCWDXIVSOQM-UHFFFAOYSA-N 0.000 claims 1
- LGHAGLPDIOJZSQ-UHFFFAOYSA-N 5-(1H-pyrazol-5-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1O)-c1ccn[nH]1 LGHAGLPDIOJZSQ-UHFFFAOYSA-N 0.000 claims 1
- LMFIWTZDOGYPQO-UHFFFAOYSA-N 5-(3-aminopyrazol-1-yl)-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound NC1=NN(C=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C LMFIWTZDOGYPQO-UHFFFAOYSA-N 0.000 claims 1
- DNADVCPATWWFGM-UHFFFAOYSA-N 5-(4-fluoropyrazol-1-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1O)-n1cc(F)cn1 DNADVCPATWWFGM-UHFFFAOYSA-N 0.000 claims 1
- LNZKMSFMFQYFAO-UHFFFAOYSA-N 5-(5-chloro-1H-pyrazol-4-yl)-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound ClC1=C(C=NN1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C LNZKMSFMFQYFAO-UHFFFAOYSA-N 0.000 claims 1
- UQMXADBFKHOXAR-UHFFFAOYSA-N 5-(5-fluoro-1H-pyrazol-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1O)-c1cn[nH]c1F UQMXADBFKHOXAR-UHFFFAOYSA-N 0.000 claims 1
- PHFTVBJWFCBELW-UHFFFAOYSA-N 5-(5-fluoro-1H-pyrazol-4-yl)-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C PHFTVBJWFCBELW-UHFFFAOYSA-N 0.000 claims 1
- VTYVULOWLCPDAE-UHFFFAOYSA-N 5-(5-methyl-1H-pyrazol-4-yl)-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CC1=C(C=NN1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)N(C1CC(NC(C1)(C)C)(C)C)C VTYVULOWLCPDAE-UHFFFAOYSA-N 0.000 claims 1
- PXCHKBILLARLLX-UHFFFAOYSA-N 5-(6-methoxypyrimidin-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound COC1=CC(=NC=N1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C PXCHKBILLARLLX-UHFFFAOYSA-N 0.000 claims 1
- WBWIUOYKHMWYFU-UHFFFAOYSA-N 5-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound FC1=C(C=CC(=C1F)C=1C=NNC=1)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C WBWIUOYKHMWYFU-UHFFFAOYSA-N 0.000 claims 1
- XJWLUMIGMIGLLC-UHFFFAOYSA-N 5-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine hydrochloride Chemical compound Cl.CN(C1CC(C)(C)NC(C)(C)C1)c1cnc(cn1)-c1ccc(-c2cn[nH]c2)c(F)c1F XJWLUMIGMIGLLC-UHFFFAOYSA-N 0.000 claims 1
- XSUNNOLPPMCQNM-UHFFFAOYSA-N 5-[2,3-difluoro-4-(4-methylimidazol-1-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound FC1=C(C=CC(=C1F)N1C=NC(=C1)C)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C XSUNNOLPPMCQNM-UHFFFAOYSA-N 0.000 claims 1
- BEMFMPBESBUDOW-UHFFFAOYSA-N 5-[2,5-dichloro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound ClC1=C(C=C(C(=C1)C=1C=NNC=1)Cl)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C BEMFMPBESBUDOW-UHFFFAOYSA-N 0.000 claims 1
- ZVTDOQWCYFJQAL-UHFFFAOYSA-N 5-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound FC1=C(C=C(C(=C1)C=1C=NNC=1)F)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C ZVTDOQWCYFJQAL-UHFFFAOYSA-N 0.000 claims 1
- GQXWQGYXNSISOF-UHFFFAOYSA-N 5-[2-fluoro-5-methyl-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound FC1=C(C=C(C(=C1)C=1C=NNC=1)C)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C GQXWQGYXNSISOF-UHFFFAOYSA-N 0.000 claims 1
- ZNFRTMGFKOPSIR-UHFFFAOYSA-N 5-[3,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound FC=1C=C(C=C(C=1C=1C=NNC=1)F)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C ZNFRTMGFKOPSIR-UHFFFAOYSA-N 0.000 claims 1
- NIBRAOVIPJXQHW-UHFFFAOYSA-N 5-[3-fluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound FC=1C=C(C=CC=1C=1C=NNC=1)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C NIBRAOVIPJXQHW-UHFFFAOYSA-N 0.000 claims 1
- QFBTZAZRFWCMTG-UHFFFAOYSA-N 5-[5-chloro-2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazin-2-amine Chemical compound ClC=1C(=CC(=C(C=1)C=1N=CC(=NC=1)N(C1CC(NC(C1)(C)C)(C)C)C)F)C=1C=NNC=1 QFBTZAZRFWCMTG-UHFFFAOYSA-N 0.000 claims 1
- AAJPZNKNQJJTKH-UHFFFAOYSA-N 5-imidazo[1,2-a]pyrazin-6-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CC1(C)CC(CC(C)(C)N1)NC1=NC=C(N=C1)C1=C(O)C=C(C=C1)C1=CN2C=CN=C2C=N1 AAJPZNKNQJJTKH-UHFFFAOYSA-N 0.000 claims 1
- YOURWMUJBGHWJG-UHFFFAOYSA-N 5-imidazo[1,2-b]pyridazin-6-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CC1(C)CC(CC(C)(C)N1)NC1=NC=C(N=C1)C1=C(O)C=C(C=C1)C1=NN2C=CN=C2C=C1 YOURWMUJBGHWJG-UHFFFAOYSA-N 0.000 claims 1
- HPEBYVKMECBKSL-UHFFFAOYSA-N 5-imidazol-1-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound N1(C=NC=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C HPEBYVKMECBKSL-UHFFFAOYSA-N 0.000 claims 1
- RTELLJFZTFWNSE-UHFFFAOYSA-N 5-imidazol-1-yl-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound CN(C1CC(C)(C)NC(C)(C)C1)c1cnc(cn1)-c1ccc(cc1O)-n1ccnc1 RTELLJFZTFWNSE-UHFFFAOYSA-N 0.000 claims 1
- ZCILNELTDVTXEM-UHFFFAOYSA-N 5-pyridin-2-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound N1=C(C=CC=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C ZCILNELTDVTXEM-UHFFFAOYSA-N 0.000 claims 1
- GSNOMESXIOXXJF-UHFFFAOYSA-N 5-pyridin-3-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C GSNOMESXIOXXJF-UHFFFAOYSA-N 0.000 claims 1
- PHVQAAMYKMYCFZ-UHFFFAOYSA-N 5-pyridin-4-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C PHVQAAMYKMYCFZ-UHFFFAOYSA-N 0.000 claims 1
- KLRZPNFBFXYMIL-UHFFFAOYSA-N 5-pyrimidin-2-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenol Chemical compound N1=C(N=CC=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C KLRZPNFBFXYMIL-UHFFFAOYSA-N 0.000 claims 1
- XXHJACUVXZBAHX-UHFFFAOYSA-N CN(C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O)C1CC(NC(C1)(C)C)(C)C Chemical compound CN(C=1N=CC(=NC=1)C1=C(C=C(C=C1)C=1C=NNC=1)O)C1CC(NC(C1)(C)C)(C)C XXHJACUVXZBAHX-UHFFFAOYSA-N 0.000 claims 1
- RFYNOSZOQAMUOK-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C RFYNOSZOQAMUOK-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- APSLUPXFNWDZNC-UHFFFAOYSA-N N-tert-butyl-1-[5-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]pyrazin-2-yl]pyrrolidin-3-amine Chemical compound C(C)(C)(C)NC1CN(CC1)C1=NC=C(N=C1)C1=C(C(=C(C=C1)C=1C=NNC=1)F)F APSLUPXFNWDZNC-UHFFFAOYSA-N 0.000 claims 1
- PDIDVOFMELOGGH-UHFFFAOYSA-N N-tert-butyl-1-[5-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]pyrazin-2-yl]pyrrolidin-3-amine dihydrochloride Chemical compound Cl.Cl.CC(C)(C)NC1CCN(C1)c1cnc(cn1)-c1ccc(-c2cn[nH]c2)c(F)c1F PDIDVOFMELOGGH-UHFFFAOYSA-N 0.000 claims 1
- WOIZIPCMOCBZBO-UHFFFAOYSA-N N-tert-butyl-1-[5-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]pyrazin-2-yl]pyrrolidin-3-amine dihydrochloride Chemical compound Cl.Cl.CC(C)(C)NC1CCN(C1)c1cnc(cn1)-c1cc(F)c(cc1F)-c1cn[nH]c1 WOIZIPCMOCBZBO-UHFFFAOYSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- QIWWIXNCPDYEJP-UHFFFAOYSA-N [2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]-5-(triazol-2-yl)phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)NC1=NC=C(N=C1)C1=C(OC=O)C=C(C=C1)N1N=CC=N1 QIWWIXNCPDYEJP-UHFFFAOYSA-N 0.000 claims 1
- FXDAWMJWIUPBSD-UHFFFAOYSA-N [5-(1-methylpyrazol-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound C(=O)OC1=C(C=CC(=C1)C=1C=NN(C=1)C)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C FXDAWMJWIUPBSD-UHFFFAOYSA-N 0.000 claims 1
- UVBXTCOTFIZBHE-UHFFFAOYSA-N [5-(1H-pyrazol-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1cn[nH]c1 UVBXTCOTFIZBHE-UHFFFAOYSA-N 0.000 claims 1
- IBMAILOZWWNVKT-UHFFFAOYSA-N [5-(1H-pyrazol-5-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1ccn[nH]1 IBMAILOZWWNVKT-UHFFFAOYSA-N 0.000 claims 1
- HURNPEQOZUBPSS-UHFFFAOYSA-N [5-(4-fluoropyrazol-1-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-n1cc(F)cn1 HURNPEQOZUBPSS-UHFFFAOYSA-N 0.000 claims 1
- ZDTULKQFWWTJBO-UHFFFAOYSA-N [5-(5-fluoro-1H-pyrazol-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1cn[nH]c1F ZDTULKQFWWTJBO-UHFFFAOYSA-N 0.000 claims 1
- NYDUCOVDAAROBE-UHFFFAOYSA-N [5-(6-methoxypyrimidin-4-yl)-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound COc1cc(ncn1)-c1ccc(c(OC=O)c1)-c1cnc(NC2CC(C)(C)NC(C)(C)C2)cn1 NYDUCOVDAAROBE-UHFFFAOYSA-N 0.000 claims 1
- JUILYRQXBWZWDC-UHFFFAOYSA-N [5-imidazo[1,2-a]pyrazin-6-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1cn2ccnc2cn1 JUILYRQXBWZWDC-UHFFFAOYSA-N 0.000 claims 1
- YJKFHESCRFFOIO-UHFFFAOYSA-N [5-imidazo[1,2-b]pyridazin-6-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1ccc2nccn2n1 YJKFHESCRFFOIO-UHFFFAOYSA-N 0.000 claims 1
- UOYQEAQPHOWXSJ-UHFFFAOYSA-N [5-imidazol-1-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-n1ccnc1 UOYQEAQPHOWXSJ-UHFFFAOYSA-N 0.000 claims 1
- SJHTYWAUBLWORY-UHFFFAOYSA-N [5-pyridin-2-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1ccccn1 SJHTYWAUBLWORY-UHFFFAOYSA-N 0.000 claims 1
- VVHBDZBUFVONLN-UHFFFAOYSA-N [5-pyridin-3-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1cccnc1 VVHBDZBUFVONLN-UHFFFAOYSA-N 0.000 claims 1
- QPCHTSAXCSKMHV-UHFFFAOYSA-N [5-pyridin-4-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound CC1(C)CC(CC(C)(C)N1)Nc1cnc(cn1)-c1ccc(cc1OC=O)-c1ccncc1 QPCHTSAXCSKMHV-UHFFFAOYSA-N 0.000 claims 1
- VIOQLPSVXJWYCC-UHFFFAOYSA-N [5-pyrimidin-2-yl-2-[5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrazin-2-yl]phenyl] formate Chemical compound C(=O)OC1=C(C=CC(=C1)C1=NC=CC=N1)C1=NC=C(N=C1)NC1CC(NC(C1)(C)C)(C)C VIOQLPSVXJWYCC-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (16)
- 式(I)の化合物、またはその形態を含む化合物であって、化合物の形態が、その塩、水和物、溶媒和物、ラセミ化合物、鏡像異性体、ジアステレオ異性体、立体異性体および互変異性体形態からなる群から選択される、化合物。
(式中、
Xは、CHR1a、C=O、O、NR1bまたは結合であり、
R1aが、水素、ハロゲン、ヒドロキシル、シアノ、C1-4アルキル、重水素-C1-4アルキル、ハロ-C1-4アルキル、アミノおよびヒドロキシル-C1-4アルキルから独立して選択され、
R1bが、水素、C1-4アルキル、重水素-C1-4アルキルおよびハロ-C1-4アルキルから独立して選択され、
Bは、ヘテロシクリルであり、
ヘテロシクリルが、N、OまたはSから独立して選択される1、2または3個のヘテロ原子環員を有する飽和または部分的不飽和3~7員環の単環式、6~10員環の二環式または13~16員環の多環式環系であり、R2からそれぞれ選択される1、2、3、4または5個の置換基でそれぞれ置換されていてもよく、
R2が、ハロゲン、C1-4アルキル、重水素-C1-4アルキル、アミノ、C1-4アルキル-アミノおよび(C1-4アルキル)2-アミノから独立して選択され、
R3は、ハロゲン、ヒドロキシル、シアノ、C1-4アルキル、重水素-C1-4アルキル、ハロ-C1-4アルキル、アミノ、C1-4アルキル-アミノ、(C1-4アルキル)2-アミノ、C1-4アルコキシ、ハロ-C1-4アルコキシ、ヘテロアリール、ヘテロシクリルおよびフェニルから独立して選択され、
ヘテロアリールが、N、OまたはSから独立して選択される1、2、3または4個のヘテロ原子環員を有する3~7員環の単環式、または6~10員環の二環式環系であり、
ヘテロシクリルが、N、OまたはSから独立して選択される1、2または3個のヘテロ原子環員を有する飽和または部分的不飽和3~7員環の単環式、6~10員環の二環式または13~16員環の多環式環系であり、
フェニル、ヘテロアリールまたはヘテロシクリルの各例が、R4からそれぞれ選択される1または2個の置換基で置換されていてもよく、
nは、1、2または3であり、
R4が、ハロゲン、ヒドロキシル、シアノ、C1-4アルキル、重水素-C1-4アルキル、ハロ-C1-4アルキル、アミノ、C1-4アルキル-アミノ、(C1-4アルキル)2-アミノ、C1-4アルコキシおよびハロ-C1-4アルコキシから独立して選択される) - Xが、NR1bおよび結合から選択される、請求項1に記載の化合物。
- Bが、アゼチジニル、テトラヒドロフラニル、ピロリジニル、ピペリジニル、ピペラジニル、1,4-ジアゼパニル、1,2-ジヒドロピリジニル、1,2,5,6-テトラヒドロピリジニル、1,2,3,6-テトラヒドロピリジニル、ヘキサヒドロシクロペンタピロール-(1H)-イル、ヘキサヒドロピロロ[3,2-b]ピロール-(2H)-イル、ヘキサヒドロピロロ[3,4-b]ピロール-(2H)-イル、(3aS,6aS)-ヘキサヒドロピロロ[3,4-b]ピロール-(2H)-イル、ヘキサヒドロピロロ[3,4-b]ピロール-(1H)-イル、(3aS,6aS)-ヘキサヒドロピロロ[3,4-b]ピロール-(1H)-イル、(3aR,6aR)-ヘキサヒドロピロロ[3,4-b]ピロール-(1H)-イル、ヘキサヒドロピロロ[3,4-c]ピロール-(1H)-イル、(3aR,6aS)-ヘキサヒドロピロロ[3,4-c]ピロール-(1H)-イル、オクタヒドロ-2H-ピロロ[3,4-c]ピリジニル、オクタヒドロ-5H-ピロロ[3,2-c]ピリジニル、オクタヒドロ-6H-ピロロ[3,4-b]ピリジニル、(4aR,7aR)-オクタヒドロ-6H-ピロロ[3,4-b]ピリジニル、(4aS,7aS)-オクタヒドロ-6H-ピロロ[3,4-b]ピリジニル、ヘキサヒドロピロロ[1,2-a]ピラジン-(2H)-オン、ヘキサヒドロピロロ[1,2-a]ピラジン-(1H)-イル、(7R,8aS)-ヘキサヒドロピロロ[1,2-a]ピラジン-(1H)-イル、(8aS)-ヘキサヒドロピロロ[1,2-a]ピラジン-(1H)-イル、(8aR)-ヘキサヒドロピロロ[1,2-a]ピラジン-(1H)-イル、ヘキサヒドロ-1H-シクロブタ[1.2-c:1,4-c’]ジピロール-(3H)-イル、(8aS)-オクタヒドロピロロ[1,2-a]ピラジン-(1H)-イル、(8aR)-オクタヒドロピロロ[1,2-a]ピラジン-(1H)-イル、オクタヒドロ-2H-ピリド[1,2-a]ピラジニル、ヘキサヒドロピロロ[3,4-b][1,4]オキサジン-(2H)-イル、5-アザスピロ[2.4]ヘプタニル、2-オキサ-6-アザスピロ[3.4]オクタニル、3-アザビシクロ[3.1.0]ヘキサニル、8-アザビシクロ[3.2.1]オクタニル、(1R,5S)-8-アザビシクロ[3.2.1]オクタニル、8-アザビシクロ[3.2.1]オクタ-2-エン-イル、(1R,5S)-8-アザビシクロ[3.2.1]オクタ-2-エン-イル、9-アザビシクロ[3.3.1]ノナニル、(1R,5S)-9-アザビシクロ[3.3.1]ノナニル、2,5-ジアザビシクロ[2.2.1]ヘプタニル、(1S,4S)-2,5-ジアザビシクロ[2.2.1]ヘプタニル、1,4-ジアザビシクロ[3.1.1]ヘプタニル、3,6-ジアザビシクロ[3.2.0]ヘプタニル、2,5-ジアザビシクロ[2.2.2]オクタニル、1,4-ジアザビシクロ[3.2.1]オクタニル、3,8-ジアザビシクロ[3.2.1]オクタニル、(1R,5S)-3,8-ジアザビシクロ[3.2.1]オクタニル、1,4-ジアザビシクロ[3.2.2]ノナニル、アザスピロ[3.3]ヘプタニル、4,7-ジアザスピロ[2.5]オクタニル、2,6-ジアザスピロ[3.3]ヘプタン-2-イル、2,6-ジアザスピロ[3.4]オクタニル、1,7,-ジアザスピロ[4.4]ノナニル、1,7-ジアザスピロ[3.5]ノナニル、2,6-ジアザスピロ[3.5]ノナニル、2,7-ジアザスピロ[3.5]ノナニル、5,8-ジアザスピロ[3.5]ノナニル、2,7-ジアザスピロ[4.4]ノナニル、2,7-ジアザスピロ[4.5]デカニル、2,8-ジアザスピロ[4.5]デカニル、6,9-ジアザスピロ[4.5]デシル、および7-アザジスピロ[5.1.58.36]ヘキサデカニルから選択され、1、2、3、4または5個のR2置換基で置換されていてもよい、請求項1に記載の化合物。
- Bが、ピロリジニル、ピペリジニル、ヘキサヒドロピロロ[3,4-c]ピロール-(1H)-イル、8-アザビシクロ[3.2.1]オクタニル、2,6-ジアザスピロ[3.4]オクタニルおよび7-アザジスピロ[5.1.58.36]ヘキサデカニルから選択され、1、2、3、4または5個のR2置換基で置換されていてもよい、請求項1に記載の化合物。
- R3が、チエニル、1H-ピラゾリル、1H-イミダゾリル、1,3-チアゾリル、オキサゾリル、1,2,4-オキサジアゾリル、1,2,4-チアジアゾリル、1H-1,2,3-トリアゾリル、2H-1,2,3-トリアゾリル、1H-1,2,4-トリアゾリル、1H-テトラゾリル、2H-テトラゾリル、ピリジニル、ピリジン-2(1H)-オン-イル、ピリミジニル、ピリミジン-4(3H)-オン-イル、ピリダジニル、ピリダジン-3(2H)-オン-イル、1,2,4-トリアジニル、1,3,5-トリアジニル、1H-インドリル、1H-インダゾリル、2H-インダゾリル、インドリジニル、ベンゾフラニル、ベンゾチエニル、1H-ベンゾイミダゾリル、1,3-ベンゾオキサゾリル、1,3-ベンゾチアゾリル、1,3-ベンゾジオキソリル、1,2,3-ベンゾトリアゾリル、9H-プリニル、フロ[3,2-b]ピリジニル、フロ[3,2-c]ピリジニル、フロ[2,3-c]ピリジニル、1,3-オキサゾロ[5,4-b]ピリジニル、チエノ[3,2-c]ピリジニル、チエノ[2,3-d]ピリミジニル、1H-ピロロ[2,3-b]ピリジニル、1H-ピロロ[2,3-c]ピリジニル、ピロロ[1,2-a]ピリミジニル、ピロロ[1,2-a]ピラジニル、ピロロ[1,2-b]ピリダジニル、ピラゾロ[1,5-a]ピリジン-イル、ピラゾロ[1,5-a]ピリジニル、1H-ピラゾロ[3,4-b]ピラジニル、1H-ピラゾロ[3,4-b]ピリジニル、1H-ピラゾロ[3,4-b]ピリジニル、1H-ピラゾロ[3,4-c]ピリジニル、1H-ピラゾロ[3,4-c]ピリジニル、1H-ピラゾロ[4,3-b]ピリジニル、1H-ピラゾロ[4,3-b]ピリジニル、1H-ピラゾロ[4,3-d]ピリミジニル、2H-ピラゾロ[4,3-b]ピリジニル、2H-ピラゾロ[4,3-c]ピリジン-イル、5H-ピロロ[2,3-b]ピラジニル、ピラゾロ[1,5-a]ピラジニル、イミダゾ[1,2-a]ピリジニル、イミダゾ[1,2-a]ピリジニル、イミダゾ[1,2-a]ピリミジニル、イミダゾ[1,2-a]ピリミジニル、イミダゾ[1,2-c]ピリミジニル、イミダゾ[1,2-b]ピリダジニル、イミダゾ[1,2-b]ピリダジニル、イミダゾ[1,2-a]ピラジニル、イミダゾ[1,2-a]ピラジニル、1H-イミダゾ[4,5-b]ピリジニル、3H-イミダゾ[4,5-b]ピリジニル、イミダゾ[2,1-b][1,3]チアゾリル、イミダゾ[2,1-b][1,3,4]チアジアゾリル、[1,3]オキサゾロ[4,5-b]ピリジニル、[1,2,3]トリアゾロ[1,5-a]ピリジニル、[1,2,3]トリアゾロ[1,5-a]ピリジニル、1H-[1,2,3]トリアゾロ[4,5-b]ピリジニル、3H-[1,2,3]トリアゾロ[4,5-b]ピリジニル、テトラゾロ[1,5-a]ピリジニル、テトラゾロ[1,5-b]ピリダジニル、キノリニル、イソキノリニル、およびキノキサリニルから選択され、1または2個のR4置換基で置換されていてもよいヘテロアリールである、請求項1に記載の化合物。
- R3が、1H-ピラゾリル、1H-イミダゾリル、2H-1,2,3-トリアゾリル、1H-1,2,4-トリアゾリル、ピリジニル、ピリジン-2(1H)-オン-イル、ピリミジニル、1,3,5-トリアジニル、イミダゾ[1,2-b]ピリダジニルおよびイミダゾ[1,2-α]ピラジニルから選択され、1または2個のR4置換基で置換されていてもよいヘテロアリールである、請求項1に記載の化合物。
- 化合物の形態が、塩酸塩、臭化水素酸塩、トリフルオロ酢酸塩、ギ酸塩、二塩酸塩、三塩酸塩、四塩酸塩、二臭化水素酸塩および二トリフルオロ酢酸塩から選択される化合物塩である、請求項1に記載の化合物。
- 4-(3-ヒドロキシ-4-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェニル)ピリジン-2-オール;
5-(1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)オキシ]ピラジン-2-イル}フェノール;
2-{5-[(7-アザジスピロ[5.1.58.36]ヘキサデカン-15-イル)(メチル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール;
5-[2,5-ジクロロ-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
5-(1H-イミダゾール-1-イル)-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
2-[5-(ヘキサヒドロピロロ[3,4-c]ピロール-2(1H)-イル)ピラジン-2-イル]-5-(1H-ピラゾール-4-イル)フェノール;
2-{5-[(ピペリジン-4-イル)オキシ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール;
2-{5-[(ピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール;
2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-[5-(トリフルオロメチル)-1H-ピラゾール-4-イル]フェノール;
2-[2,3-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]-5-[(2,2,6,6-テトラメチルピペリジン-4-イル)オキシ]ピラジン;
5-[2-フルオロ-5-メチル-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
5-(5-メチル-1H-ピラゾール-4-イル)-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-[2,3-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
5-(3-アミノ-1H-ピラゾール-1-イル)-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-[2,5-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
5-[3-フルオロ-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
5-[3,5-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
4-(3-ヒドロキシ-4-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェニル)-1-メチルピリジン-2(1H)-オン;
2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-1-イル)フェノール;
2-{5-[メチル(ピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール;
2-[5-(2,6-ジアザスピロ[3.4]オクタン-2-イル)ピラジン-2-イル]-5-(1H-ピラゾール-4-イル)フェノール;
4-フルオロ-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール;
5-[5-クロロ-2-フルオロ-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
4-フルオロ-5-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-2-(1H-ピラゾール-4-イル)ベンゾニトリル;
2-[5-(8-アザビシクロ[3.2.1]オクタ-3-イルオキシ)ピラジン-2-イル]-5-(1H-ピラゾール-4-イル)フェノール;
2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール;
5-(1-メチル-1H-ピラゾール-4-イル)-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-[1-(2H3)メチル-1H-ピラゾール-4-イル]-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
(5-(2-ヒドロキシ-4-(1H-ピラゾール-4-イル)フェニル)ピラジン-2-イル)(2,2,6,6-テトラメチルピペリジン-4-イル)メタノン;
2-(5-(2-ヒドロキシ-4-(1H-ピラゾール-4-イル)フェニル)ピラジン-2-イル)-2-(2,2,6,6-テトラメチルピペリジン-4-イル)アセトニトリル;
2-(5-(アミノ(2,2,6,6-テトラメチルピペリジン-4-イル)メチル)ピラジン-2-イル)-5-(1H-ピラゾール-4-イル)フェノール;
2-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)-5-(1,3,5-トリアジン-2-イル)フェノール;
4-(3-ヒドロキシ-4-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェニル)-1,3,5-トリアジン-2-オール;
5-(4-アミノ-1,3,5-トリアジン-2-イル)-2-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェノール;
5-(4-クロロ-1,3,5-トリアジン-2-イル)-2-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェノール;
5-(5-クロロ-1H-ピラゾール-4-イル)-2-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェノール;
4-(3-ヒドロキシ-4-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェニル)-1H-ピラゾール-5-カルボニトリル;
5-(1,5-ジメチル-1H-ピラゾール-4-イル)-2-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェノール;
5-(5-クロロ-1-メチル-1H-ピラゾール-4-イル)-2-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェノール;
4-(3-ヒドロキシ-4-(5-(メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ)ピラジン-2-イル)フェニル)-1-メチル-1H-ピラゾール-5-カルボニトリル;
5-[2,3-ジフルオロ-4-(4-メチル-1H-イミダゾール-1-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
5-[2,5-ジフルオロ-4-(3-メチル-1H-1,2,4-トリアゾール-1-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン;
5-(3-フルオロ-1H-ピラゾール-4-イル)-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(ピリジン-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(ピリジン-3-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(ピリミジン-2-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(ピリジン-2-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(6-メトキシピリミジン-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(1H-イミダゾール-1-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(2H-1,2,3-トリアゾール-2-イル)フェノール;
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール;
5-(イミダゾ[1,2-a]ピラジン-6-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(1-メチル-1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(1-メチル-1H-ピラゾール-3-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(イミダゾ[1,2-b]ピリダジン-6-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(5-フルオロ-1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(1H-ピラゾール-3-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
5-(4-フルオロ-1H-ピラゾール-1-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール;
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-[1-(2H3)メチル-1H-ピラゾール-4-イル]フェノール;
2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(2H-1,2,3-トリアゾール-2-イル)フェノール;
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-(1-メチル-1H-ピラゾール-4-イル)フェノール;
N-tert-ブチル-1-{5-[2,3-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]ピラジン-2-イル}ピロリジン-3-アミン;
N-tert-ブチル-1-{5-[2,5-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]ピラジン-2-イル}ピロリジン-3-アミン;および
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-(3-フルオロ-1H-ピラゾール-4-イル)フェノール
からなる群から選択される化合物であって、化合物の形態が、その塩、水和物、溶媒和物、ラセミ化合物、鏡像異性体、ジアステレオ異性体、立体異性体および互変異性体形態からなる群から選択される、化合物。 - 化合物の形態が、
5-(1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)オキシ]ピラジン-2-イル}フェノール塩酸塩、
2-[5-(ヘキサヒドロピロロ[3,4-c]ピロール-2(1H)-イル)ピラジン-2-イル]-5-(1H-ピラゾール-4-イル)フェノール四塩酸塩、
2-{5-[(ピペリジン-4-イル)オキシ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール三塩酸塩、
2-{5-[(ピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール四塩酸塩、
2-[2,3-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]-5-[(2,2,6,6-テトラメチルピペリジン-4-イル)オキシ]ピラジン三塩酸塩、
5-[2,3-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]-N-メチル-N-(2,2,6,6-テトラメチルピペリジン-4-イル)ピラジン-2-アミン塩酸塩、
2-[5-(8-アザビシクロ[3.2.1]オクタ-3-イルオキシ)ピラジン-2-イル]-5-(1H-ピラゾール-4-イル)フェノール塩酸塩、
2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール臭化水素酸塩、
5-[1-(2H3)メチル-1H-ピラゾール-4-イル]-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール二塩酸塩、
5-(3-フルオロ-1H-ピラゾール-4-イル)-2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノール二塩酸塩、
5-(ピリジン-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(ピリジン-3-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(ピリミジン-2-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(ピリジン-2-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(6-メトキシピリミジン-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(1H-イミダゾール-1-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(2H-1,2,3-トリアゾール-2-イル)フェノールギ酸塩、
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-(1H-ピラゾール-4-イル)フェノール二塩酸塩、
5-(イミダゾ[1,2-a]ピラジン-6-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(1-メチル-1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(イミダゾ[1,2-b]ピリダジン-6-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(5-フルオロ-1H-ピラゾール-4-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(1H-ピラゾール-3-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
5-(4-フルオロ-1H-ピラゾール-1-イル)-2-{5-[(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}フェノールギ酸塩、
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-[1-(2H3)メチル-1H-ピラゾール-4-イル]フェノール二塩酸塩、
2-{5-[メチル(2,2,6,6-テトラメチルピペリジン-4-イル)アミノ]ピラジン-2-イル}-5-(2H-1,2,3-トリアゾール-2-イル)フェノール二塩酸塩、
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-(1-メチル-1H-ピラゾール-4-イル)フェノール二塩酸塩、
N-tert-ブチル-1-{5-[2,3-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]ピラジン-2-イル}ピロリジン-3-アミン二塩酸塩、
N-tert-ブチル-1-{5-[2,5-ジフルオロ-4-(1H-ピラゾール-4-イル)フェニル]ピラジン-2-イル}ピロリジン-3-アミン二塩酸塩、および
2-{5-[3-(tert-ブチルアミノ)ピロリジン-1-イル]ピラジン-2-イル}-5-(3-フルオロ-1H-ピラゾール-4-イル)フェノール二塩酸塩
からなる群から選択される化合物塩、またはその形態であって、化合物の形態が、その塩、水和物、溶媒和物、ラセミ化合物、鏡像異性体、ジアステレオ異性体、立体異性体および互変異性体形態からなる群から選択される、請求項6に記載の化合物。 - 有効量の請求項1、8または9のいずれか1項に記載の化合物を含む、それを必要とする対象においてHDを処置または寛解するための医薬組成物。
- 化合物の有効量が、約0.001mg/kg/日~約500mg/kg/日の範囲である、請求項10に記載の医薬組成物。
- それを必要とする対象においてHDを処置または寛解するための医薬の製造における、請求項1、8または9のいずれか1項に記載の化合物の使用であって、前記医薬が有効量の前記化合物を含む、使用。
- 医薬における化合物の有効量が、約0.001mg/kg/日~約500mg/kg/日の範囲である、請求項12に記載の使用。
- それを必要とする対象においてHDを処置または寛解するための医薬組成物の調製における、請求項1、8または9のいずれか1項に記載の化合物の使用であって、前記医薬組成物が1つまたは複数の医薬として許容できる賦形剤と混和した式(I)の化合物、またはその形態の有効量を含む、使用。
- 医薬組成物における化合物の有効量が、約0.001mg/kg/日~約500mg/kg/日の範囲である、請求項14に記載の使用。
- 1つまたは複数の医薬として許容できる賦形剤と混和した、請求項1、8または9のいずれか1項に記載の化合物を含む、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862648699P | 2018-03-27 | 2018-03-27 | |
US62/648,699 | 2018-03-27 | ||
PCT/US2019/024068 WO2019191092A1 (en) | 2018-03-27 | 2019-03-26 | Compounds for treating huntington's disease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021519318A JP2021519318A (ja) | 2021-08-10 |
JPWO2019191092A5 true JPWO2019191092A5 (ja) | 2022-03-31 |
JP7399870B2 JP7399870B2 (ja) | 2023-12-18 |
Family
ID=68060393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020552026A Active JP7399870B2 (ja) | 2018-03-27 | 2019-03-26 | ハンチントン病を処置するための化合物 |
JP2020551538A Active JP7399869B2 (ja) | 2018-03-27 | 2019-03-27 | ハンチントン病を処置するための化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020551538A Active JP7399869B2 (ja) | 2018-03-27 | 2019-03-27 | ハンチントン病を処置するための化合物 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20210009590A1 (ja) |
EP (1) | EP3773552A4 (ja) |
JP (2) | JP7399870B2 (ja) |
KR (2) | KR20210005559A (ja) |
CN (2) | CN112135815A (ja) |
AU (2) | AU2019243048A1 (ja) |
BR (2) | BR112020019373A2 (ja) |
CA (2) | CA3094703A1 (ja) |
EA (2) | EA202092001A1 (ja) |
IL (2) | IL277497A (ja) |
MX (2) | MX2020009957A (ja) |
SG (2) | SG11202009212WA (ja) |
WO (2) | WO2019191092A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
GB2587457B (en) | 2017-08-04 | 2022-06-01 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
IL275490B2 (en) | 2017-12-22 | 2024-05-01 | Ravenna Pharmaceuticals Inc | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
AU2019294478B2 (en) * | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
KR20210135241A (ko) | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
WO2020163409A1 (en) * | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
MX2022005254A (es) | 2019-11-01 | 2022-06-29 | Novartis Ag | El uso de un modulador de empalme para un tratamiento que retrasa la progresion de la enfermedad de huntington. |
CN115768762A (zh) * | 2020-04-09 | 2023-03-07 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
MX2022013856A (es) | 2020-05-13 | 2023-04-05 | Chdi Foundation Inc | Moduladores htt para tratar la enfermedad de huntington. |
TW202216671A (zh) * | 2020-06-25 | 2022-05-01 | 瑞士商諾華公司 | 1,4—二取代的嗒𠯤化合物之製造方法 |
CA3188104A1 (en) * | 2020-08-05 | 2022-02-10 | Michael Luzzio | Compositions for modulating splicing |
WO2022031998A2 (en) * | 2020-08-05 | 2022-02-10 | Skyhawk Therapeutics, Inc. | Process for the preparation of intermediates useful in the preparation of compounds that modulate splicing |
WO2022032007A2 (en) * | 2020-08-05 | 2022-02-10 | Skyhawk Therapeutics, Inc. | Process for the preparation of intermediates useful in the preparation of compounds that modulate splicing |
TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
BR112023022451A2 (pt) | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
WO2023028536A1 (en) * | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
WO2023034836A1 (en) * | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
CN116063307A (zh) * | 2021-10-29 | 2023-05-05 | 中国药科大学 | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 |
TW202327604A (zh) * | 2022-01-07 | 2023-07-16 | 大陸商藥捷安康(南京)科技股份有限公司 | Nlrp3發炎小體抑制劑及其應用 |
WO2024017924A1 (en) * | 2022-07-21 | 2024-01-25 | F. Hoffmann-La Roche Ag | Nlrp3 inhibitors |
Family Cites Families (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637271A (ja) | 1963-04-04 | 1900-01-01 | ||
US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
FR2567518B1 (fr) * | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
WO1993023398A1 (en) | 1992-05-13 | 1993-11-25 | E.I. Du Pont De Nemours And Company | Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides |
NZ266386A (en) | 1993-05-11 | 1997-11-24 | Univ North Carolina | Use of antisense rna oligonucleotides in regulating gene expression |
JPH11510478A (ja) | 1995-06-06 | 1999-09-14 | アボツト・ラボラトリーズ | キノリジノン型化合物 |
US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
CA2269561C (en) | 1998-04-22 | 2007-06-05 | Dainippon Ink And Chemicals, Inc. | Naphthalene derivative and liquid crystal composition comprising the same |
US6630488B1 (en) | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
EP1652839A3 (en) | 1999-10-28 | 2006-07-05 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
EP1257537B1 (en) | 2000-01-24 | 2007-05-30 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
CA2437942C (en) | 2000-11-09 | 2013-06-11 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
KR100947185B1 (ko) | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
US20050009843A1 (en) | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
JP2005516005A (ja) | 2001-12-07 | 2005-06-02 | バーテクス ファーマスーティカルズ インコーポレイテッド | Gsk−3阻害剤として有用なピリミジンベースの化合物 |
GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
US7423133B2 (en) | 2002-08-23 | 2008-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent glycosides and methods for their use |
DE60311853T2 (de) | 2002-09-30 | 2007-06-21 | Neurosearch A/S | Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung |
US20070078144A1 (en) | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
KR20060069356A (ko) | 2003-06-20 | 2006-06-21 | 카이론 코포레이션 | 항암제로서 피리디노[1,2-α]피리미딘-4-온 화합물 |
GB0315494D0 (en) * | 2003-07-02 | 2003-08-06 | Biofocus Plc | Compounds which bind to the active site of protein kinase enzymes |
EP1651631A1 (en) | 2003-08-01 | 2006-05-03 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137203A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US7309699B2 (en) * | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
CN101723949B (zh) | 2003-12-24 | 2013-10-23 | 生物区科学管理控股有限公司 | 用于治疗呼吸道合胞体病毒感染的多环试剂 |
SE0400184D0 (sv) | 2004-01-30 | 2004-01-30 | Fyrkloevern Scandinavia Ab | New therapeutical use |
TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
CN1964717A (zh) | 2004-04-08 | 2007-05-16 | 神经能质公司 | 经取代∴啉-4-基胺 |
MXPA06012829A (es) | 2004-05-04 | 2007-01-26 | Warner Lambert Co | Pirido[2,3-d]pirimidin-7-onas sustituidas con pirrolilo y derivados de las mismas como agentes terapeuticos. |
CN101146798A (zh) | 2005-01-21 | 2008-03-19 | 詹森药业有限公司 | 用作雌激素受体调节剂的新的杂环苯并[c]色烯衍生物 |
US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
JP2006219453A (ja) | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
JP5121707B2 (ja) | 2005-07-04 | 2013-01-16 | ハイ ポイント ファーマシューティカルズ,エルエルシー | 新規医薬 |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
US8258109B2 (en) | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
WO2007058894A2 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
US8173658B2 (en) * | 2005-12-06 | 2012-05-08 | Neurosearch A/S | Diazabicycylic aryl derivatives and their medical use |
EP1968968A1 (en) | 2005-12-21 | 2008-09-17 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
WO2007089584A2 (en) | 2006-01-26 | 2007-08-09 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
AU2007229492B2 (en) | 2006-03-28 | 2011-11-03 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
WO2007133756A2 (en) | 2006-05-15 | 2007-11-22 | Neurogen Corporation | Crf1 receptor ligands comprising heteroaryl fused bicycles |
US7910578B2 (en) | 2006-05-23 | 2011-03-22 | Neurosearch A/S | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use |
AU2007275682B2 (en) | 2006-07-20 | 2012-05-17 | Amgen Inc. | Substituted pyridone compounds and methods of use |
WO2008013997A2 (en) | 2006-07-27 | 2008-01-31 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
PL2066653T3 (pl) | 2006-08-03 | 2013-02-28 | Rottapharm Biotech Srl | Pochodne 6-1H-imidazo-chinazoliny i chinoliny, nowe silne środki przeciwbólowe i przeciwzapalne |
JP2010507619A (ja) | 2006-10-25 | 2010-03-11 | ノイロサーチ アクティーゼルスカブ | オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用 |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
KR20100049698A (ko) | 2006-12-22 | 2010-05-12 | 아벡사 리미티드 | 바이사이클 피리미디논 및 그 용도 |
WO2008083226A2 (en) | 2006-12-28 | 2008-07-10 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
AU2008304231A1 (en) | 2007-09-27 | 2009-04-02 | Albany Molecular Research, Inc. | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
JP5410431B2 (ja) | 2007-09-27 | 2014-02-05 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス(セエネイオ) | イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 |
US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
JP2011524383A (ja) | 2008-06-20 | 2011-09-01 | ロッタファルム・ソシエタ・ペル・アチオニ | 6−1h−イミダゾ−キナゾリンおよびキノリン誘導体、新規mao阻害剤およびイミダゾリンレセプターリガンド |
EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
CA2729663A1 (en) | 2008-07-02 | 2010-01-07 | Avexa Limited | Compounds having antiviral properties |
WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
WO2010024903A1 (en) | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
AU2009303441A1 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
EP2396327A1 (en) | 2009-02-11 | 2011-12-21 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
FR2945289A1 (fr) | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
JP2012530084A (ja) | 2009-06-19 | 2012-11-29 | アボット・ラボラトリーズ | ジアザホモアダマンタン誘導体およびこの使用方法 |
CN102625809B (zh) | 2009-09-11 | 2015-06-24 | Isis制药公司 | 亨廷顿表达的调节 |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
WO2011057204A2 (en) | 2009-11-06 | 2011-05-12 | The Johns Hopkins University | Lrrk2-mediated neuronal toxicity |
WO2011062853A1 (en) | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
WO2011085990A1 (en) | 2010-01-13 | 2011-07-21 | Institut Pasteur Korea | Anti - infective pyrido (1,2 -a) pyrimidines |
WO2011097641A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
DK2534248T3 (en) | 2010-02-08 | 2018-11-19 | Ionis Pharmaceuticals Inc | SELECTIVE REDUCTION OF ALLELVARIANS |
US9006198B2 (en) | 2010-02-08 | 2015-04-14 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
JP5981428B2 (ja) | 2010-07-19 | 2016-08-31 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 筋緊張性ジストロフィー・プロテインキナーゼ(dmpk)発現の調整 |
WO2012019106A2 (en) | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
CN102617548A (zh) | 2011-01-31 | 2012-08-01 | 北京赛林泰医药技术有限公司 | 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用 |
WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
WO2012109395A1 (en) | 2011-02-08 | 2012-08-16 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2013019938A1 (en) | 2011-08-02 | 2013-02-07 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as eaat2 activators |
WO2013022984A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
EP2560008B1 (en) | 2011-08-18 | 2016-11-30 | Korea Institute of Science and Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
WO2013033223A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
WO2013059606A1 (en) | 2011-10-21 | 2013-04-25 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
MX2014006409A (es) | 2011-11-28 | 2014-07-30 | Novartis Ag | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. |
KR102057351B1 (ko) | 2011-12-30 | 2019-12-18 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
JP6193888B2 (ja) | 2012-01-26 | 2017-09-06 | ピーティーシー セラピューティクス, インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
DK2812004T3 (en) | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
KR102099997B1 (ko) | 2012-03-01 | 2020-04-13 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
NZ700928A (en) | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
CA2878895A1 (en) | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
EP2906255B1 (en) | 2012-10-12 | 2023-02-22 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
WO2014059356A2 (en) | 2012-10-12 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
CA2889494C (en) | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
JP6255711B2 (ja) | 2012-11-01 | 2018-01-10 | 株式会社リコー | エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子 |
US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
EP2951304B1 (en) | 2013-02-04 | 2020-07-08 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
WO2014135244A1 (en) | 2013-03-05 | 2014-09-12 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
EP2997028A1 (en) | 2013-05-14 | 2016-03-23 | F.Hoffmann-La Roche Ag | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
EP3013345B1 (en) | 2013-06-25 | 2017-11-22 | F. Hoffmann-La Roche AG | Compounds for treating spinal muscular atrophy |
PL3027600T3 (pl) | 2013-07-31 | 2022-08-08 | Novartis Ag | 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn |
CN105392790B (zh) | 2013-08-19 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途 |
WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
WO2015136947A1 (en) * | 2014-03-14 | 2015-09-17 | Raqualia Pharma Inc. | Azaspiro derivatives as trpm8 antagonists |
ES2946754T3 (es) | 2014-03-19 | 2023-07-25 | Amydis Diagnostics Inc | Agentes para detección de amiloides y métodos para utilizar los mismos |
AU2015261046C1 (en) | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
WO2015195811A2 (en) | 2014-06-17 | 2015-12-23 | Novozymes A/S | Biological phosphorus removal from wastewater |
CN106459067B (zh) | 2014-06-25 | 2019-05-31 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的咪唑并[1,2-a]吡嗪-1基苯甲酰胺化合物 |
BR112017011791A2 (pt) | 2014-12-02 | 2018-02-27 | Bayer Cropscience Aktiengesellschaft | compostos bicíclicos como agentes de controle de pragas |
HUE043842T2 (hu) | 2014-12-24 | 2019-09-30 | Uniqure Ip Bv | RNAi-indukált huntingtin gén szuppresszió |
PT3244891T (pt) | 2015-01-16 | 2022-10-20 | Massachusetts Gen Hospital | Compostos para melhorar o splicing do arnm |
EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
GB201502567D0 (en) | 2015-02-16 | 2015-04-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
WO2016144351A1 (en) | 2015-03-11 | 2016-09-15 | E. I. Du Pont De Nemours And Company | Heterocycle-substituted bicyclic azole pesticides |
GB201506933D0 (en) | 2015-04-23 | 2015-06-10 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
MX2018005041A (es) | 2015-11-12 | 2018-08-01 | Hoffmann La Roche | Compuestos para tratar la esclerosis lateral amiotrofica. |
US10383867B2 (en) | 2015-11-28 | 2019-08-20 | Russell Dahl | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders |
ES2879995T3 (es) * | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
WO2018022473A1 (en) | 2016-07-25 | 2018-02-01 | Wave Life Sciences Ltd. | Phasing |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
WO2018187209A1 (en) | 2017-04-03 | 2018-10-11 | Acceleron Pharma Inc. | Compositions and methods for treating spinal muscular atrophy |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
GB2587457B (en) | 2017-08-04 | 2022-06-01 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
US20200392161A1 (en) | 2018-02-21 | 2020-12-17 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
EP3768680A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
WO2019183367A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
MX2020014315A (es) | 2018-06-27 | 2021-05-27 | Ptc Therapeutics Inc | Compuestos de heteroarilo para tratar la enfermedad de huntington. |
JP2022525417A (ja) | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
MX2022005254A (es) | 2019-11-01 | 2022-06-29 | Novartis Ag | El uso de un modulador de empalme para un tratamiento que retrasa la progresion de la enfermedad de huntington. |
CN115768762A (zh) | 2020-04-09 | 2023-03-07 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
AU2021380758A1 (en) | 2020-11-12 | 2023-06-15 | Ptc Therapeutics Inc. | Novel rna transcript |
AU2022320725A1 (en) | 2021-07-30 | 2024-02-22 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
-
2019
- 2019-03-26 KR KR1020207027340A patent/KR20210005559A/ko not_active Application Discontinuation
- 2019-03-26 JP JP2020552026A patent/JP7399870B2/ja active Active
- 2019-03-26 SG SG11202009212WA patent/SG11202009212WA/en unknown
- 2019-03-26 BR BR112020019373-9A patent/BR112020019373A2/pt unknown
- 2019-03-26 US US17/040,751 patent/US20210009590A1/en active Pending
- 2019-03-26 CN CN201980022422.XA patent/CN112135815A/zh active Pending
- 2019-03-26 CA CA3094703A patent/CA3094703A1/en active Pending
- 2019-03-26 WO PCT/US2019/024068 patent/WO2019191092A1/en unknown
- 2019-03-26 MX MX2020009957A patent/MX2020009957A/es unknown
- 2019-03-26 AU AU2019243048A patent/AU2019243048A1/en active Pending
- 2019-03-26 EA EA202092001A patent/EA202092001A1/ru unknown
- 2019-03-27 SG SG11202009211VA patent/SG11202009211VA/en unknown
- 2019-03-27 US US17/040,104 patent/US11780839B2/en active Active
- 2019-03-27 EP EP19777730.3A patent/EP3773552A4/en active Pending
- 2019-03-27 AU AU2019243943A patent/AU2019243943A1/en active Pending
- 2019-03-27 BR BR112020019264-3A patent/BR112020019264A2/pt unknown
- 2019-03-27 KR KR1020207027339A patent/KR20210005558A/ko not_active Application Discontinuation
- 2019-03-27 MX MX2020009956A patent/MX2020009956A/es unknown
- 2019-03-27 EA EA202092003A patent/EA202092003A1/ru unknown
- 2019-03-27 WO PCT/US2019/024278 patent/WO2019191229A1/en unknown
- 2019-03-27 JP JP2020551538A patent/JP7399869B2/ja active Active
- 2019-03-27 CA CA3094700A patent/CA3094700A1/en active Pending
- 2019-03-27 CN CN201980022516.7A patent/CN112203653A/zh active Pending
-
2020
- 2020-09-22 IL IL277497A patent/IL277497A/en unknown
- 2020-09-22 IL IL277498A patent/IL277498A/en unknown
-
2023
- 2023-06-16 US US18/211,134 patent/US20230331725A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019191092A5 (ja) | ||
US10934302B1 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
JPWO2019191229A5 (ja) | ||
KR101812357B1 (ko) | Cdk4/6의 억제제로서의 피롤로피리미딘 화합물 | |
JP2020522570A5 (ja) | ||
AU2022209304A1 (en) | Heteroaryl compounds for treating Huntington's disease | |
BR112021001292A2 (pt) | compostos heterobicíclicos para inibir a atividade de shp2 | |
ES2904773T3 (es) | Compuestos de diazaindol | |
JPWO2020005877A5 (ja) | ||
JPWO2020005873A5 (ja) | ||
JP2021503004A5 (ja) | ||
JP2014506929A5 (ja) | ||
EP3317269A1 (en) | Bicyclic lactams and methods of use thereof | |
AU2020277027A1 (en) | Compounds for treating huntington's disease | |
JP2011500774A5 (ja) | ||
CN114728935A (zh) | Shp2抑制剂 | |
JP2015504057A5 (ja) | ||
JPWO2020081848A5 (ja) | ||
IL297044A (en) | Compounds for the treatment of Huntington's disease | |
JPWO2020231977A5 (ja) | ||
RU2021111918A (ru) | Модуляторы моноацилглицерин-липазы | |
KR20160045819A (ko) | 알킨일 알코올 및 이용 방법 |